Oral Upadacitinib Combined with Phototherapy for Progressive Vitiligo in 7-Year-Old Children: A Two-Case Report.
- 1Institute of Dermatology, Guangzhou Medical University, Guangzhou, Guangdong, People's Republic of China.
- 2Department of Dermatology, Guangzhou Dermatology Hospital, Guangzhou, Guangdong, People's Republic of China.
Abstract
We report two 7-year-old children with progressive vitiligo despite prior topical therapy and phototherapy; one patient had also received low-dose systemic corticosteroid therapy. Oral upadacitinib, a selective Janus kinase 1 (JAK1) inhibitor, was initiated at 15 mg once daily in both patients in combination with phototherapy. The boy underwent 308-nm excimer laser therapy every 3 days, whereas the girl received narrowband ultraviolet B phototherapy at the same interval. Before treatment, baseline screening was performed to exclude contraindications, and no clinically significant abnormalities were identified. After 4 weeks, both patients showed rapid repigmentation and a reduction in lesion extent. The boy with facial vitiligo achieved near-complete repigmentation (Vitiligo Area Scoring Index [VASI] reduced from 0.4 to nearly 0), while the girl with non-segmental vitiligo involving the trunk and extremities showed progressive repigmentation (VASI reduced from 2.7 to approximately 1.0 by week 8). Follow-up laboratory tests during upadacitinib treatment, including complete blood counts, liver and renal function tests, and lipid profiles, remained within normal limits, and no clinically significant adverse events were observed during 18-20 weeks of treatment. Oral upadacitinib combined with phototherapy was associated with rapid disease stabilization and repigmentation in these two children, although larger and longer-term studies remain necessary.
Related
- Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies
- Development of an Experimental Protocol for Combined Electroporation and Phototherapy Treatment Against Melanoma Cells
- Combination therapy of carbon dioxide laser with topical halometason cream and 308 nm excimer laser for the treatment of vitiligo: an optimized combined treatment protocol.
- Comparative longitudinal evaluation of DIMS, progressive addition and single-vision lenses on myopia progression, binocular and visual performance in Spanish children
- Economic burden of immune-mediated and psychiatric comorbidities in patients with newly diagnosed vitiligo
BibTeX
@article{jiang2026oral,
title = {{Oral Upadacitinib Combined with Phototherapy for Progressive Vitiligo in 7-Year-Old Children: A Two-Case Report.}},
author = {Yu Jiang and Zhirong Shu and Shilin Deng and Tingnan Chen and Xiaohong Lin and Jingyao Liang and Yaping Tang},
journal = {Clinical, cosmetic and investigational dermatology},
year = {2026},
month = oct,
doi = {10.2147/ccid.s636036},
url = {https://europepmc.org/article/MED/42894796},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Oral Upadacitinib Combined with Phototherapy for Progressive Vitiligo in 7-Year-Old Children: A Two-Case Report.
AU - Yu Jiang
AU - Zhirong Shu
AU - Shilin Deng
AU - Tingnan Chen
AU - Xiaohong Lin
AU - Jingyao Liang
AU - Yaping Tang
PY - 2026
DA - 2026/10/14
JO - Clinical, cosmetic and investigational dermatology
DO - 10.2147/ccid.s636036
UR - https://europepmc.org/article/MED/42894796
AB - We report two 7-year-old children with progressive vitiligo despite prior topical therapy and phototherapy; one patient had also received low-dose systemic corticosteroid therapy. Oral upadacitinib, a selective Janus kinase 1 (JAK1) inhibitor, was initiated at 15 mg once daily in both patients in combination with phototherapy. The boy underwent 308-nm excimer laser therapy every 3 days, whereas the girl received narrowband ultraviolet B phototherapy at the same interval. Before treatment, baseline screening was performed to exclude contraindications, and no clinically significant abnormalities were identified. After 4 weeks, both patients showed rapid repigmentation and a reduction in lesion extent. The boy with facial vitiligo achieved near-complete repigmentation (Vitiligo Area Scoring Index [VASI] reduced from 0.4 to nearly 0), while the girl with non-segmental vitiligo involving the trunk and extremities showed progressive repigmentation (VASI reduced from 2.7 to approximately 1.0 by week 8). Follow-up laboratory tests during upadacitinib treatment, including complete blood counts, liver and renal function tests, and lipid profiles, remained within normal limits, and no clinically significant adverse events were observed during 18-20 weeks of treatment. Oral upadacitinib combined with phototherapy was associated with rapid disease stabilization and repigmentation in these two children, although larger and longer-term studies remain necessary.
SN - 1178-7015
ER -